everolimus accord 5 mg tabletki
accord healthcare polska sp. z o.o. - everolimusum - tabletki - 5 mg
everolimus accord 10 mg tabletki
accord healthcare polska sp. z o.o. - everolimusum - tabletki - 10 mg
bortezomib medac 3,5 mg proszek do sporządzania roztworu do wstrzykiwań
medac gmbh - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 3,5 mg
telmisartan orion 40 mg tabletki
orion corporation - telmisartanum - tabletki - 40 mg
bortezomib medac 1 mg proszek do sporządzania roztworu do wstrzykiwań
medac gmbh - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 1 mg
zoledronic acid accord 4 mg/100 ml roztwór do infuzji
accord healthcare polska sp. z o.o. - acidum zoledronicum - roztwór do infuzji - 4 mg/100 ml
verzenios
eli lilly nederland b.v. - abemaciclib - nowotwory piersi - Środki przeciwnowotworowe - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
everolimus krka 2,5 mg tabletki
krka, d.d., novo mesto d.o.o. - everolimusum - tabletki - 2,5 mg
everolimus krka 5 mg tabletki
krka, d.d., novo mesto d.o.o. - everolimusum - tabletki - 5 mg
everolimus krka 10 mg tabletki
krka, d.d., novo mesto d.o.o. - everolimusum - tabletki - 10 mg